[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Deutsche Bank AG Raises Stake in Tenet Healthcare Corporation (NYSE:THC):
[TEXT]
Deutsche Bank AG lifted its holdings in shares of Tenet Healthcare Corporation (NYSE:THC – Free Report) by 4.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,399 shares of the company’s stock after purchasing an additional 3,351 shares during the quarter. Deutsche Bank AG’s holdings in Tenet Healthcare were worth $10,679,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in shares of Tenet Healthcare by 22.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,493,532 shares of the company’s stock worth $188,524,000 after purchasing an additional 272,906 shares during the period. AQR Capital Management LLC grew its holdings in shares of Tenet Healthcare by 20.8% during the 4th quarter. AQR Capital Management LLC now owns 872,117 shares of the company’s stock worth $110,087,000 after purchasing an additional 150,361 shares during the period. Northern Trust Corp grew its holdings in shares of Tenet Healthcare by 22.0% during the 4th quarter. Northern Trust Corp now owns 848,049 shares of the company’s stock worth $107,049,000 after purchasing an additional 152,671 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Tenet Healthcare by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 815,126 shares of the company’s stock worth $109,634,000 after purchasing an additional 13,057 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in shares of Tenet Healthcare by 45.2% during the 1st quarter. Victory Capital Management Inc. now owns 736,252 shares of the company’s stock worth $99,026,000 after purchasing an additional 229,197 shares during the period. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Get Tenet Healthcare alerts:

Insider Activity

In other Tenet Healthcare news, EVP Paola M. Arbour sold 7,738 shares of Tenet Healthcare stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $173.00, for a total value of $1,338,674.00. Following the transaction, the executive vice president directly owned 20,110 shares in the company, valued at approximately $3,479,030. This trade represents a 27.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director J Robert Kerrey sold 1,222 shares of Tenet Healthcare stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $164.96, for a total value of $201,581.12. Following the completion of the transaction, the director owned 22,377 shares in the company, valued at $3,691,309.92. This trade represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,659 shares of company stock worth $7,068,604 over the last ninety days. 0.81% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

THC has been the topic of several research reports. Bank of America increased their target price on Tenet Healthcare from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Raymond James Financial reissued an “outperform” rating and set a $200.00 target price (up previously from $185.00) on shares of Tenet Healthcare in a research note on Wednesday, July 23rd. Mizuho increased their target price on Tenet Healthcare from $184.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, July 11th. Wall Street Zen raised Tenet Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Royal Bank Of Canada lifted their price objective on shares of Tenet Healthcare from $183.00 to $189.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $191.88.

Get Our Latest Stock Analysis on Tenet Healthcare

Tenet Healthcare Trading Down 0.2%

NYSE:THC opened at $172.04 on Friday. The stock’s 50 day moving average price is $167.18 and its 200 day moving average price is $148.40. The company has a market capitalization of $15.20 billion, a PE ratio of 11.01, a P/E/G ratio of 0.74 and a beta of 1.52. The company has a quick ratio of 1.63, a current ratio of 1.71 and a debt-to-equity ratio of 2.39. Tenet Healthcare Corporation has a 52-week low of $109.82 and a 52-week high of $185.25.

Tenet Healthcare (NYSE:THC – Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $1.18. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.16 billion. Tenet Healthcare had a return on equity of 24.69% and a net margin of 7.17%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.31 EPS. On average, research analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

About Tenet Healthcare

(Free Report)

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

See Also

Want to see what other hedge funds are holding THC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenet Healthcare Corporation (NYSE:THC – Free Report).

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/16/deutsche-bank-ag-raises-stake-in-tenet-healthcare-corporation-nysethc/


[TITLE]Cetera Investment Advisers Has $580,000 Stock Holdings in Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH):
[TEXT]
Cetera Investment Advisers boosted its position in shares of Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH – Free Report) by 84.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,691 shares of the company’s stock after buying an additional 6,722 shares during the quarter. Cetera Investment Advisers’ holdings in Invesco Dorsey Wright Healthcare Momentum ETF were worth $580,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Prosperity Consulting Group LLC lifted its stake in shares of Invesco Dorsey Wright Healthcare Momentum ETF by 23.0% in the 4th quarter. Prosperity Consulting Group LLC now owns 7,393 shares of the company’s stock valued at $296,000 after purchasing an additional 1,384 shares during the period. BNP Paribas acquired a new position in shares of Invesco Dorsey Wright Healthcare Momentum ETF in the 4th quarter valued at $84,000. Focus Partners Wealth acquired a new position in shares of Invesco Dorsey Wright Healthcare Momentum ETF in the 4th quarter valued at $200,000. Advisory Services Network LLC acquired a new position in shares of Invesco Dorsey Wright Healthcare Momentum ETF in the 4th quarter valued at $220,000. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Invesco Dorsey Wright Healthcare Momentum ETF by 100.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 12,840 shares of the company’s stock valued at $507,000 after purchasing an additional 6,420 shares during the period.

Get Invesco Dorsey Wright Healthcare Momentum ETF alerts:

Invesco Dorsey Wright Healthcare Momentum ETF Stock Down 0.4%

PTH opened at $39.05 on Friday. Invesco Dorsey Wright Healthcare Momentum ETF has a 12 month low of $33.56 and a 12 month high of $48.63. The company has a fifty day simple moving average of $38.25 and a 200 day simple moving average of $38.93. The stock has a market cap of $95.28 million, a P/E ratio of 35.21 and a beta of 0.85.
[Source link]: https://www.etfdailynews.com/2025/08/16/cetera-investment-advisers-has-580000-stock-holdings-in-invesco-dorsey-wright-healthcare-momentum-etf-nasdaqpth/


[TITLE]Prestige Consumer Healthcare Inc. $PBH Shares Sold by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers decreased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 3.7% during the 1st quarter, Holdings Channel reports. The fund owned 5,093 shares of the company’s stock after selling 196 shares during the quarter. Cetera Investment Advisers’ holdings in Prestige Consumer Healthcare were worth $438,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PBH. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Prestige Consumer Healthcare in the fourth quarter valued at approximately $84,932,000. BNP Paribas Financial Markets raised its holdings in Prestige Consumer Healthcare by 1,073.3% in the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company’s stock valued at $15,923,000 after acquiring an additional 186,524 shares in the last quarter. GAMMA Investing LLC raised its holdings in Prestige Consumer Healthcare by 11,580.3% in the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company’s stock valued at $13,887,000 after acquiring an additional 160,155 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Prestige Consumer Healthcare in the fourth quarter valued at approximately $7,778,000. Finally, Congress Asset Management Co. raised its holdings in Prestige Consumer Healthcare by 9.1% in the first quarter. Congress Asset Management Co. now owns 991,580 shares of the company’s stock valued at $85,246,000 after acquiring an additional 82,838 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Get Prestige Consumer Healthcare alerts:

Prestige Consumer Healthcare Stock Up 0.7%

PBH stock opened at $65.06 on Monday. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a twelve month low of $62.95 and a twelve month high of $90.04. The company’s 50 day moving average is $77.27 and its two-hundred day moving average is $81.62. The stock has a market cap of $3.20 billion, a P/E ratio of 15.27, a PEG ratio of 2.05 and a beta of 0.43.

Wall Street Analyst Weigh In

Prestige Consumer Healthcare ( NYSE:PBH Get Free Report ) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%. The business’s revenue was down 6.6% on a year-over-year basis. During the same quarter last year, the business posted $0.90 earnings per share. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Several analysts recently weighed in on PBH shares. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Wall Street Zen cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $93.33.

Read Our Latest Research Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Company Profile

(Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Articles

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/18/prestige-consumer-healthcare-inc-pbh-shares-sold-by-cetera-investment-advisers/

================================================================================

[TITLE]Deutsche Bank AG Raises Stake in Tenet Healthcare Corporation (NYSE:THC):
[TEXT]
Deutsche Bank AG lifted its holdings in shares of Tenet Healthcare Corporation (NYSE:THC – Free Report) by 4.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,399 shares of the company’s stock after purchasing an additional 3,351 shares during the quarter. Deutsche Bank AG’s holdings in Tenet Healthcare were worth $10,679,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in shares of Tenet Healthcare by 22.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,493,532 shares of the company’s stock worth $188,524,000 after purchasing an additional 272,906 shares during the period. AQR Capital Management LLC grew its holdings in shares of Tenet Healthcare by 20.8% during the 4th quarter. AQR Capital Management LLC now owns 872,117 shares of the company’s stock worth $110,087,000 after purchasing an additional 150,361 shares during the period. Northern Trust Corp grew its holdings in shares of Tenet Healthcare by 22.0% during the 4th quarter. Northern Trust Corp now owns 848,049 shares of the company’s stock worth $107,049,000 after purchasing an additional 152,671 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Tenet Healthcare by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 815,126 shares of the company’s stock worth $109,634,000 after purchasing an additional 13,057 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in shares of Tenet Healthcare by 45.2% during the 1st quarter. Victory Capital Management Inc. now owns 736,252 shares of the company’s stock worth $99,026,000 after purchasing an additional 229,197 shares during the period. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Get Tenet Healthcare alerts:

Insider Activity

In other Tenet Healthcare news, EVP Paola M. Arbour sold 7,738 shares of Tenet Healthcare stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $173.00, for a total value of $1,338,674.00. Following the transaction, the executive vice president directly owned 20,110 shares in the company, valued at approximately $3,479,030. This trade represents a 27.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director J Robert Kerrey sold 1,222 shares of Tenet Healthcare stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $164.96, for a total value of $201,581.12. Following the completion of the transaction, the director owned 22,377 shares in the company, valued at $3,691,309.92. This trade represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,659 shares of company stock worth $7,068,604 over the last ninety days. 0.81% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

THC has been the topic of several research reports. Bank of America increased their target price on Tenet Healthcare from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Raymond James Financial reissued an “outperform” rating and set a $200.00 target price (up previously from $185.00) on shares of Tenet Healthcare in a research note on Wednesday, July 23rd. Mizuho increased their target price on Tenet Healthcare from $184.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, July 11th. Wall Street Zen raised Tenet Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Royal Bank Of Canada lifted their price objective on shares of Tenet Healthcare from $183.00 to $189.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $191.88.

Get Our Latest Stock Analysis on Tenet Healthcare

Tenet Healthcare Trading Down 0.2%

NYSE:THC opened at $172.04 on Friday. The stock’s 50 day moving average price is $167.18 and its 200 day moving average price is $148.40. The company has a market capitalization of $15.20 billion, a PE ratio of 11.01, a P/E/G ratio of 0.74 and a beta of 1.52. The company has a quick ratio of 1.63, a current ratio of 1.71 and a debt-to-equity ratio of 2.39. Tenet Healthcare Corporation has a 52-week low of $109.82 and a 52-week high of $185.25.

Tenet Healthcare (NYSE:THC – Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $1.18. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.16 billion. Tenet Healthcare had a return on equity of 24.69% and a net margin of 7.17%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.31 EPS. On average, research analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

About Tenet Healthcare

(Free Report)

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

See Also

Want to see what other hedge funds are holding THC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenet Healthcare Corporation (NYSE:THC – Free Report).

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/16/deutsche-bank-ag-raises-stake-in-tenet-healthcare-corporation-nysethc/


[TITLE]Cetera Investment Advisers Has $580,000 Stock Holdings in Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH):
[TEXT]
Cetera Investment Advisers boosted its position in shares of Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH – Free Report) by 84.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,691 shares of the company’s stock after buying an additional 6,722 shares during the quarter. Cetera Investment Advisers’ holdings in Invesco Dorsey Wright Healthcare Momentum ETF were worth $580,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Prosperity Consulting Group LLC lifted its stake in shares of Invesco Dorsey Wright Healthcare Momentum ETF by 23.0% in the 4th quarter. Prosperity Consulting Group LLC now owns 7,393 shares of the company’s stock valued at $296,000 after purchasing an additional 1,384 shares during the period. BNP Paribas acquired a new position in shares of Invesco Dorsey Wright Healthcare Momentum ETF in the 4th quarter valued at $84,000. Focus Partners Wealth acquired a new position in shares of Invesco Dorsey Wright Healthcare Momentum ETF in the 4th quarter valued at $200,000. Advisory Services Network LLC acquired a new position in shares of Invesco Dorsey Wright Healthcare Momentum ETF in the 4th quarter valued at $220,000. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Invesco Dorsey Wright Healthcare Momentum ETF by 100.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 12,840 shares of the company’s stock valued at $507,000 after purchasing an additional 6,420 shares during the period.

Get Invesco Dorsey Wright Healthcare Momentum ETF alerts:

Invesco Dorsey Wright Healthcare Momentum ETF Stock Down 0.4%

PTH opened at $39.05 on Friday. Invesco Dorsey Wright Healthcare Momentum ETF has a 12 month low of $33.56 and a 12 month high of $48.63. The company has a fifty day simple moving average of $38.25 and a 200 day simple moving average of $38.93. The stock has a market cap of $95.28 million, a P/E ratio of 35.21 and a beta of 0.85.
[Source link]: https://www.etfdailynews.com/2025/08/16/cetera-investment-advisers-has-580000-stock-holdings-in-invesco-dorsey-wright-healthcare-momentum-etf-nasdaqpth/


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]abrdn Healthcare Investors (NYSE:HQH) Shares Acquired by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers increased its stake in abrdn Healthcare Investors (NYSE:HQH – Free Report) by 14.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 53,638 shares of the financial services provider’s stock after buying an additional 6,943 shares during the period. Cetera Investment Advisers’ holdings in abrdn Healthcare Investors were worth $871,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Nexus Investment Management ULC acquired a new position in abrdn Healthcare Investors during the first quarter valued at approximately $64,000. CoreCap Advisors LLC raised its stake in shares of abrdn Healthcare Investors by 175.8% during the fourth quarter. CoreCap Advisors LLC now owns 7,262 shares of the financial services provider’s stock valued at $117,000 after purchasing an additional 4,629 shares during the period. Comerica Bank raised its stake in shares of abrdn Healthcare Investors by 17.3% during the fourth quarter. Comerica Bank now owns 7,504 shares of the financial services provider’s stock valued at $120,000 after purchasing an additional 1,105 shares during the period. Elequin Capital LP purchased a new stake in shares of abrdn Healthcare Investors during the fourth quarter valued at approximately $121,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of abrdn Healthcare Investors during the first quarter valued at approximately $189,000. 32.60% of the stock is owned by institutional investors and hedge funds.

Get abrdn Healthcare Investors alerts:

abrdn Healthcare Investors Trading Up 1.5%

HQH opened at $16.14 on Thursday. The firm’s 50 day moving average is $15.73 and its 200-day moving average is $16.12. abrdn Healthcare Investors has a 52-week low of $13.77 and a 52-week high of $19.79.

abrdn Healthcare Investors Cuts Dividend
[Source link]: https://www.etfdailynews.com/2025/08/14/abrdn-healthcare-investors-nysehqh-shares-acquired-by-cetera-investment-advisers/

================================================================================

[TITLE]Atria Wealth Solutions Inc. Invests $215,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX):
[TEXT]
Atria Wealth Solutions Inc. acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 8,882 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.

Other institutional investors have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the first quarter worth
[Source link]: https://www.etfdailynews.com/2025/08/17/atria-wealth-solutions-inc-invests-215000-in-catalyst-pharmaceuticals-inc-nasdaqcprx/


[TITLE]US Bancorp DE Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT):
[TEXT]
US Bancorp DE lifted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 248.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,763 shares of the company’s stock after purchasing an additional 16,937 shares during the period. US Bancorp DE’s holdings in Phathom Pharmaceuticals were worth $149,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PHAT. Kera Capital Partners Inc. grew its holdings in Phathom Pharmaceuticals by 11.2% during the 1st quarter. Kera Capital Partners Inc. now owns 29,849 shares of the company’s stock worth $187,000 after acquiring an additional 3,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Phathom Pharmaceuticals by 18.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,149 shares of the company’s stock valued at $180,000 after purchasing an additional 3,408 shares during the last quarter. ProShare Advisors LLC raised its position in Phathom Pharmaceuticals by 36.3% during the 4th quarter. ProShare Advisors LLC now owns 14,289 shares of the company’s stock worth $116,000 after buying an additional 3,804 shares during the last quarter. GAMMA Investing LLC raised its position in Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock worth $29,000 after buying an additional 4,050 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Phathom Pharmaceuticals by 21.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,641 shares of the company’s stock worth $209,000 after buying an additional 4,592 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors.

Get Phathom Pharmaceuticals alerts:

Wall Street Analysts Forecast Growth

PHAT has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Phathom Pharmaceuticals in a research report on Monday, June 9th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. Guggenheim lowered their target price on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group reduced their price target on Phathom Pharmaceuticals from $10.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. Finally, Craig Hallum lifted their price target on Phathom Pharmaceuticals from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, June 9th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $17.50.

Phathom Pharmaceuticals Trading Down 2.2%

Shares of PHAT opened at $10.24 on Friday. The firm has a market cap of $726.47 million, a P/E ratio of -2.16 and a beta of 0.45. Phathom Pharmaceuticals, Inc. has a 12-month low of $2.21 and a 12-month high of $19.71. The company’s 50-day moving average price is $9.29 and its 200 day moving average price is $6.40.

Phathom Pharmaceuticals Profile

(Free Report)

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Further Reading

Want to see what other hedge funds are holding PHAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report).

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/17/us-bancorp-de-increases-stake-in-phathom-pharmaceuticals-inc-nasdaqphat/


[TITLE]Maryland State Retirement & Pension System Makes New $471,000 Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR):
[TEXT]
Maryland State Retirement & Pension System acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 36,992 shares of the biotechnology company’s stock, valued at approximately $471,000.

Several other large investors have also recently made changes to their positions in the business. Ontario Teachers Pension Plan Board purchased a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at approximately $583,000. Charles Schwab Investment Management Inc. raised its holdings in Arrowhead Pharmaceuticals by 1.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,035,290 shares of the biotechnology company’s stock worth $13,190,000 after acquiring an additional 17,570 shares during the last quarter. Vanguard Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after acquiring an additional 1,018,273 shares during the last quarter. Privium Fund Management B.V. raised its holdings in Arrowhead Pharmaceuticals by 65.3% in the 1st quarter. Privium Fund Management B.V. now owns 629,214 shares of the biotechnology company’s stock worth $8,016,000 after acquiring an additional 248,628 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Arrowhead Pharmaceuticals in the 1st quarter worth approximately $133,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Get Arrowhead Pharmaceuticals alerts:

Insider Activity

In other news, insider James C. Hamilton sold 9,389 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $20.00, for a total transaction of $187,780.00. Following the completion of the sale, the insider owned 262,122 shares of the company’s stock, valued at $5,242,440. The trade was a 3.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Trading Up 9.2%

NASDAQ:ARWR opened at $20.51 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $27.34. The company has a 50 day simple moving average of $16.71 and a two-hundred day simple moving average of $15.94. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a market cap of $2.84 billion, a PE ratio of -16.02, a price-to-earnings-growth ratio of 72.16 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $29.01 million. During the same period last year, the firm posted ($1.38) earnings per share. Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analysts Set New Price Targets

ARWR has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 18th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.14.

View Our Latest Analysis on Arrowhead Pharmaceuticals
[Source link]: https://www.etfdailynews.com/2025/08/16/maryland-state-retirement-pension-system-makes-new-471000-investment-in-arrowhead-pharmaceuticals-inc-nasdaqarwr/


[TITLE]XTX Topco Ltd Invests $110,000 in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA):
[TEXT]
XTX Topco Ltd purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 19,941 shares of the biotechnology company’s stock, valued at approximately $110,000.

Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC increased its stake in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 2,274 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth approximately $40,000. Squarepoint Ops LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $66,000. Velan Capital Investment Management LP purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $75,000. Finally, Corton Capital Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth approximately $77,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Get Enanta Pharmaceuticals alerts:

Enanta Pharmaceuticals Trading Up 2.1%

Shares of ENTA stock opened at $7.74 on Friday. The stock has a market capitalization of $165.48 million, a P/E ratio of -1.79 and a beta of 0.88. The firm’s 50 day moving average is $7.39 and its 200 day moving average is $6.46. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $13.43.

Analyst Upgrades and Downgrades

Enanta Pharmaceuticals ( NASDAQ:ENTA Get Free Report ) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The company had revenue of $18.31 million for the quarter, compared to analysts’ expectations of $16.21 million. On average, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday. Finally, HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a research note on Monday, July 28th. They set a “buy” rating and a $20.00 price target on the stock.

Read Our Latest Stock Report on ENTA

Enanta Pharmaceuticals Company Profile

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Stories

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/15/xtx-topco-ltd-invests-110000-in-enanta-pharmaceuticals-inc-nasdaqenta/

================================================================================

[TITLE]Theratechnologies receives interim order in acquisition by CB Biotechnology THTX:
[TEXT]
We use cookies to improve user experience, and analyze website traffic.

For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
[Source link]: https://thefly.com/permalinks/entry.php/id4184845/THTX-Theratechnologies-receives-interim-order-in-acquisition-by-CB-Biotechnology


[Failed to load article at https://financialpost.com/globe-newswire/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-order-in-relation-to-its-acquisition-by-cb-biotechnology-an-affiliate-of-future-pak]


[TITLE]Theratechnologies Announces Filing of Special Meeting:
[TEXT]
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.

Board unanimously recommends shareholders vote “FOR” the Arrangement.

Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.

Visit www.theratech.com
[Source link]: https://www.globenewswire.com/news-release/2025/08/18/3134927/0/en/Theratechnologies-Announces-Filing-of-Special-Meeting-Materials-and-Receipt-of-Interim-Order-in-Relation-to-its-Acquisition-by-CB-Biotechnology-an-Affiliate-of-Future-Pak.html


[TITLE]Freeze-Thaw Bags Market Trends and Investment Opportunities to 2030 - Biotechnology and Food Storage Applications Lead the Industry:
[TEXT]
Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Freeze-Thaw Bags
[Source link]: https://www.globenewswire.com/news-release/2025/08/14/3133624/28124/en/Freeze-Thaw-Bags-Market-Trends-and-Investment-Opportunities-to-2030-Biotechnology-and-Food-Storage-Applications-Lead-the-Industry.html

================================================================================

[TITLE]Applied AI in Healthcare Market 2025-2029: Key Investment Opportunities for Treatment & Care, Administrative & Operational Efficiency, Diagnostic, and Disease Prevention & Management Applications:
[TEXT]
Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Applied AI in Healthcare Market 2025-2029" has been added to ResearchAndMarkets.com's offering.

The applied AI in healthcare market is projected to experience significant growth, with an increase of USD 75.23 billion anticipated during 2024-2029, at an impressive CAGR of 37.3%. This robust expansion highlights the market's dynamic nature and the essential role of AI in transforming healthcare operations. The report offers an up-to-date analysis of the current market scenario, emerging trends, and growth drivers, alongside a detailed vendor analysis featuring approximately 25 vendors.

Key market growth is fueled by the proliferation of big data and the growing demand for actionable insights. These insights are vital for enhancing operational efficiency and mitigating clinician burnout. Additionally, continuous advancements in AI algorithms and computational infrastructure further propel market development.

The rise of generative AI in clinical and administrative workflows, coupled with the increase in multimodal AI for comprehensive patient analysis, are highlighted as key drivers of market growth. Additionally, the proliferation of AI at the edge for point-of-care diagnostics is expected to contribute to increased market demand.

The report integrates primary and secondary information from key industry participants, providing comprehensive market size data, regional segment analysis, and vendor landscapes, along with insights into key companies involved in the market.

The applied AI in healthcare market is segmented as follows:

By Component:

Solutions

Services

By Application:

Treatment and care

Administrative and operational efficiency

Diagnostic

Disease prevention and management

By End-user:

Hospitals and clinics

Research and academic institutes

By Geographical Landscape:

North America

Europe

APAC

South America

Middle East and Africa

The report covers the following key areas:

Applied AI In Healthcare Market sizing

Applied AI In Healthcare Market forecast

Applied AI In Healthcare Market industry analysis

A detailed vendor analysis is designed to help clients bolster their market positions. The report provides an in-depth evaluation of leading vendors including AiCure, Augmedix Inc., CloudMedx Inc., and many others. Insights on upcoming trends and challenges are included to inform strategic planning and leverage growth opportunities.

A selection of companies mentioned in this report includes, but is not limited to:

AiCure

Augmedix Inc

CloudMedx Inc.

Eko Devices Inc.

Enlitic Inc.

GE Healthcare Technologies Inc.

Google LLC

International Business Machines Corp.

Koninklijke Philips N.V.

Lunit Inc.

Medtronic PLC

Microsoft Corp.

NVIDIA Corp.

Oncora Medical Inc.

PathAI Inc.

Qventus Inc.

Siemens Healthineers AG

Tempus Labs Inc.

Verantos Inc.

XpertDox LLC
[Source link]: https://www.globenewswire.com/news-release/2025/08/15/3134326/28124/en/Applied-AI-in-Healthcare-Market-2025-2029-Key-Investment-Opportunities-for-Treatment-Care-Administrative-Operational-Efficiency-Diagnostic-and-Disease-Prevention-Management-Applica.html


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in Diversified Healthcare Trust (NASDAQ:DHC):
[TEXT]
Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) by 13.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,372 shares of the real estate investment trust’s stock after purchasing an additional 18,297 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.06% of Diversified Healthcare Trust worth $373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BlackBarn Capital Partners LP lifted its holdings in shares of Diversified Healthcare Trust by 41.8% during the 4th quarter. BlackBarn Capital Partners LP now owns 6,250,000 shares of the real estate investment trust’s stock valued at $14,375,000 after purchasing an additional 1,841,503 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Diversified Healthcare Trust by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 5,696,513 shares of the real estate investment trust’s stock valued at $13,105,000 after purchasing an additional 29,062 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Diversified Healthcare Trust by 9.6% during the 4th quarter. Northern Trust Corp now owns 2,134,083 shares of the real estate investment trust’s stock valued at $4,908,000 after purchasing an additional 187,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Diversified Healthcare Trust by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,060,326 shares of the real estate investment trust’s stock valued at $4,738,000 after purchasing an additional 89,415 shares during the last quarter. Finally, CastleKnight Management LP raised its stake in Diversified Healthcare Trust by 30.1% in the 4th quarter. CastleKnight Management LP now owns 1,845,842 shares of the real estate investment trust’s stock worth $4,245,000 after acquiring an additional 427,400 shares during the last quarter. Hedge funds and other institutional investors own 75.98% of the company’s stock.

Get Diversified Healthcare Trust alerts:

Diversified Healthcare Trust Stock Performance

Shares of DHC stock opened at $3.64 on Thursday. The firm has a market capitalization of $878.73 million, a price-to-earnings ratio of -3.06 and a beta of 2.52. The company has a debt-to-equity ratio of 1.42, a current ratio of 6.35 and a quick ratio of 6.35. The business has a fifty day moving average of $3.53 and a 200 day moving average of $2.93. Diversified Healthcare Trust has a 1 year low of $2.00 and a 1 year high of $4.24.

Diversified Healthcare Trust Dividend Announcement

Diversified Healthcare Trust ( NASDAQ:DHC Get Free Report ) last issued its earnings results on Monday, August 4th. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $382.71 million during the quarter, compared to analyst estimates of $382.74 million. Diversified Healthcare Trust had a negative return on equity of 14.69% and a negative net margin of 18.83%.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 14th. Investors of record on Monday, July 21st will be paid a $0.01 dividend. The ex-dividend date is Monday, July 21st. This represents a $0.04 dividend on an annualized basis and a yield of 1.1%. Diversified Healthcare Trust’s dividend payout ratio (DPR) is -3.36%.

Diversified Healthcare Trust Profile

(Free Report)

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.

Further Reading

Want to see what other hedge funds are holding DHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diversified Healthcare Trust (NASDAQ:DHC – Free Report).

Receive News & Ratings for Diversified Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diversified Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/14/mitsubishi-ufj-asset-management-co-ltd-boosts-stake-in-diversified-healthcare-trust-nasdaqdhc/


[TITLE]abrdn Healthcare Investors (NYSE:HQH) Shares Acquired by Cetera Investment Advisers:
[TEXT]
Cetera Investment Advisers increased its stake in abrdn Healthcare Investors (NYSE:HQH – Free Report) by 14.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 53,638 shares of the financial services provider’s stock after buying an additional 6,943 shares during the period. Cetera Investment Advisers’ holdings in abrdn Healthcare Investors were worth $871,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Nexus Investment Management ULC acquired a new position in abrdn Healthcare Investors during the first quarter valued at approximately $64,000. CoreCap Advisors LLC raised its stake in shares of abrdn Healthcare Investors by 175.8% during the fourth quarter. CoreCap Advisors LLC now owns 7,262 shares of the financial services provider’s stock valued at $117,000 after purchasing an additional 4,629 shares during the period. Comerica Bank raised its stake in shares of abrdn Healthcare Investors by 17.3% during the fourth quarter. Comerica Bank now owns 7,504 shares of the financial services provider’s stock valued at $120,000 after purchasing an additional 1,105 shares during the period. Elequin Capital LP purchased a new stake in shares of abrdn Healthcare Investors during the fourth quarter valued at approximately $121,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of abrdn Healthcare Investors during the first quarter valued at approximately $189,000. 32.60% of the stock is owned by institutional investors and hedge funds.

Get abrdn Healthcare Investors alerts:

abrdn Healthcare Investors Trading Up 1.5%

HQH opened at $16.14 on Thursday. The firm’s 50 day moving average is $15.73 and its 200-day moving average is $16.12. abrdn Healthcare Investors has a 52-week low of $13.77 and a 52-week high of $19.79.

abrdn Healthcare Investors Cuts Dividend
[Source link]: https://www.etfdailynews.com/2025/08/14/abrdn-healthcare-investors-nysehqh-shares-acquired-by-cetera-investment-advisers/

================================================================================

